LOTIS-9: Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients
Condition: Diffuse Large B-Cell Lymphoma
Sponsor: ADC Therapeutics SA
Full Title
Protocol ADCT-402-203: A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL)
Eligibility
Eligible patients will be ≥80 years old or ≥65 years old with cardiac comorbidities that contraindicate treatment with anthracycline drugs. The study is for the treatment of patients with previously untreated diffuse large b-cell lymphoma (DLBCL), grade 3B follicular lymphoma, or DLBCL transformed from an indolent lymphoma.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
